Anthropic · San Francisco · Claude · CNBC Technology
Anthropic ships AI drug discovery program, joining tech giants in betting on healthcare
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
◌ Single Source
Anthropic is starting an internal drug discovery program as part of an effort to develop artificial intelligence tools designed for drugmakers, becoming the latest company to try and crack the healthcare market.
Key facts
- An Anthropic spokesperson told CNBC that as a public benefit company, "They can choose programs on patient benefit, including work the commercial market overlooks
- WATCH: Why OpenAI and Anthropic may be rushing to IPO
- At an event in San Francisco on Tuesday, Anthropic's life sciences head Eric Kauderer-Abrams said the company will focus on discovering treatments for "neglected" diseases that traditional
- Kauderer-Abrams didn't say what Anthropic would do if it finds any promising drug candidates
Summary
At an event in San Francisco on Tuesday, Anthropic's life sciences head Eric Kauderer-Abrams said the company will focus on discovering treatments for "neglected" diseases that traditional biopharmaceutical companies wouldn't consider attractive targets. "We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you," Kauderer-Abrams said. Kauderer-Abrams didn't say what Anthropic would do if it finds any promising drug candidates. An Anthropic spokesperson told CNBC that as a public benefit company, "They can choose programs on patient benefit, including work the commercial market overlooks.